EUCTR2015-004317-24-IT进行中（未招募）1 期
A pilot study to assess Coronary Flow Reserve and post-vasodilatatory Myocardial Blood Flow (post-Dipi gMBF), measured by 13N-NH3 PET/CT, before and after a six months-long treatment with the ACE-inhibitor Perindopril, in moderate and high-risk HCM patients”A multicentric, interventional, open label, perspective-design, single-arm, pilot” clinical Study. - CARAPaCe (CoronAry Reserve After Perindopril in hypertophic Cardiomyopathy)
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 21
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Age in the range 18-60
- •2. Availability of a 12-lead rest-ECG, performed not
- •earlier than 60 days prior to enrollment visit (EV).
- •This is called B-ECG (Baseline-ECG), in the following
- •3. Availability of a 2-D Doppler echocardiogram,
- •performed at rest, not earlier than 60 days before of
- •EV. This is called B-ECO (Baseline - Ecocardiography in the following text.
- •4. Availability of a 13N-NH3 PET/CT myocardial
- •perfusion scan for measurement of Myocardial Blood
- •Flow (MBF), global and regional, performed not
- •earlier than 60 days before of enrollment visit, at
- •one or the other of involved clinical trial center. This
- •is called B-PET/CT (Baseline-Positron Emission
- •Tomography/Computed Tomography), in the
- •following text
- •5. Availability of lab tests (including at least:
- •a. Hematocrit and complete blood count (CBC)
- •b. blood urea nitrogen (BUN)
- •c. serum creatinine,
- •d. blood glucose,
- •e. serum potassium ion
- •performed not earlier than 60 days before of
- •enrollment visit. This is called Baseline-Blood Tests”
- •(B-BT), in the following text.
- •6. Fulfillment of 2D-echocardiographyc (as assessed by
- •B-ECO), and clinical criteria for diagnosis of HCM
- •according to the ACCF/AHA Guideline (2011) for
- •diagnosis of HCM:
- •a. maximum LV wall thickness >1.5 cm
- •b. not-dilated LV cavity
- •in the absence of clinical evidence for any other
- •cardiovascular or systemic etiology, justifying the
- •degree of myocardial hypertrophy actually seen
- •(e.g., arterial hypertension, aortic valve stenosis,
- •cardiac amyloidosis, metabolic storage diseases, as
- •detailed in the exclusion criteria).
- •7. Absence of severe, resting LV outflow tract
- •obstruction (peak gradient, measured at rest, >50
- •mmHg), as assessed by B-ECO.
- •8. Global Post-Dipi gMBF < 2.1 mL/min*gr, as assessed
- •by 13N-NH3 PET/CT myocardial perfusion scan at
- •baseline (B-PET/CT).
- •9. Stable sinus rhythm, as assessed by B-ECG.
- •10. Clear ability to understand the significance and the procedures of the Protocol and to sign a legally valid
- •informed consent.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 21
- •F.1.3 Elderly (>=65 years) no
- 另有 1 项未显示
排除标准
- •1. Women, who are pregnant or lactating
- •2. Women, i in childbearing age, not using an adequatecontraception (i.e., techniques having Pearl index<2)
- •3. Clinical evidence or previous clinical story of diseasescausing myocardial hypertrophy or similar
- •phenotypes:
- •a. Aortic stenosis
- •b. Cardiac amyloidosis
- •c. hemochromatosis
- •d. storage diseases
- •4. Coronary Artery Disease :
- •a. previous coronarography, assessing 1 or
- •more stenosis >70% of major epicardial
- •b. Clinical story for previous PTCA
- •c. Clinical story for previous CABG.
- •5. Evidence for fixed or inducible regional defect of
- •perfusion of LV, as assessed by B-PET/CT,
- •suggesting CAD, unless recent (<30 days old)
- •coronarography, negative for stenosis >70% in any
- •of the major epicardial arteries, is available.
- •6. Evidence for valvular heart disease (particularly for
- •aortic stenosis), as assessed by B-ECO.
- •7. Previous clinical story for arterial hypertension,
- •requiring antihypertensive medication
- •8. Arterial pressure >145 mmHg systolic and/or >90
- •mmHg diastolic measured at EV
- •9. Arterial pressure <110 mmHg systolic measured at EV (Enrollment Visit)
- •10. LV outflow tract obstruction, with peak of ejection
- •gradient >50 mmHg measured at rest, as assed by
- •11. Prior surgical septal myectomy or alcoholic ablation;
- •12. LV systolic dysfunction with EF <50% as assessed
- •13. Evidence for electric ventricular conduction
- •abnormalities such as LBBB, RBBB, WPW, AV blocks,Long QT, as assessed by B-ECG.
- •14. Body mass index >32 Kg/m2
- •15. Clinical evidence or clinical story for Diabetes
- •16. Clinical story for vasculitis or connective tissue
- •disease (AR, LES, SS, MCTD, Churg Strauss
- •vasculitis, ANCA-linked vasculitis, polyarterits
- •nodosa, temporal arteritis, Takayasu disease, etc.)
- •17. Clinical story for cancer of any kind unless nonmelanoma skin cancers
- •18. GFR< 60 mL/min estimated by MDRD equation and by B-BT data.
- •19. Clinical story for chronic liver disease with
- •insufficiency > class A Child-Pugh
- •20. Present evidence or previous story of neurologic
- •diseases (cerebrovascular, neurodegenerative,
- •demielinating)
- •21. Clinical story for psychiatric disorders or
- •administration (previous or present) of psychotropic
- •drugs (unless minor tranquillizers or hypnotics)
- •22. Clinical story for psychotropic drugs abuse or
- •addiction, or for alcohol abuse/addiction
- •23. Any contraindication to the administration of
- 另有 30 项未显示
研究者
相似试验
尚未招募
不适用
Evaluation of coronary blood flow in patients with severe aortic stenosis treated with transcatheter aortic valve replacementAortic stenosisACTRN12618000403235MonashHeart30
已完成
不适用
Clinical utility of coronary flow reserve assessed by phase-contrast cine magnetic resonance imaging in heart failure patientsHeart failure patientsJPRN-UMIN000033116Kanagawa Cardiovascular and respiratory Center400
已完成
不适用
Clinical utility of coronary flow reserve assessed by phase contrast cine MRI of the coronary sinus in heart failure patients with atrial fibrillatioHeart failure patients with atrial fibrillationJPRN-UMIN000033117Kanagawa Cardiovascular and respiratory Center300
Unknown
4 期
Assessment of Coronary Flow Reserve by Doppler Flow WIre in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: Differences Between the Loading Dose of Prasugrel and Ticagrelor .Non ST Elevation Myocardial InfarctionST Elevation Myocardial InfarctionAcute Coronary SyndromeUnstable AnginaNCT02032303Azienda Policlinico Umberto I88
已完成
Unknown
Coronary flow reserve evaluated by phase-contrast cine magnetic resonance imaging of the coronary sinus: A Meta-analysisJPRN-UMIN000049626Yokohama City University